Group 1 - The company, Liaoning Chengda, and its concerted actions hold a total of 1,366,927,688 shares of GF Securities, accounting for 17.97% of the total share capital of GF Securities [1]

Financial Performance - The company's operating revenue for Q3 2025 was CNY 2,765,488,918.06, a decrease of 4.27% compared to the same period last year[3]. - Total profit for the period reached CNY 706,256,154.17, an increase of 154.70% year-on-year[3]. - Net profit attributable to shareholders was CNY 647,007,965.25, reflecting a growth of 156.84% compared to the previous year[3]. - The basic earnings per share for the quarter was CNY 0.4250, up 156.80% year-on-year[4]. - Total operating revenue for the first three quarters of 2025 was approximately ¥8.11 billion, a decrease of 2.02% compared to ¥8.28 billion in the same period of 2024[19]. - Operating profit for the first three quarters of 2025 increased significantly to approximately ¥1.54 billion, up 98.73% from ¥774.70 million in 2024[20]. - Net profit for the first three quarters of 2025 reached approximately ¥1.45 billion, a substantial increase of 112.50% compared to ¥683.47 million in 2024[21]. - The net profit for the first three quarters of 2025 reached CNY 1,910,093,252.66, a significant increase from CNY 1,060,705,972.41 in the same period of 2024, representing an increase of approximately 80.5%[30]. - The total comprehensive income for the first three quarters of 2025 was CNY 1,843,297,193.50, compared to CNY 1,254,960,054.54 in 2024, indicating a growth of about 46.8%[31]. Assets and Liabilities - Total assets at the end of the period amounted to CNY 49,172,317,766.79, representing a 2.79% increase from the end of the previous year[4]. - Total assets as of September 30, 2025, amounted to CNY 49.17 billion, an increase from CNY 47.84 billion as of December 31, 2024, reflecting a growth of approximately 2.77%[15][17]. - Current assets totaled CNY 11.22 billion, slightly up from CNY 11.10 billion at the end of 2024, indicating a growth of about 1.01%[15]. - Total liabilities stood at CNY 15.61 billion, a slight increase from CNY 15.46 billion, reflecting a growth of approximately 1.01%[17]. - Total liabilities increased slightly to CNY 14,165,782,483.79 from CNY 14,051,557,520.71, indicating a growth of 0.8%[28]. - The company's total equity rose to CNY 28,118,595,168.47, up from CNY 26,302,179,467.47, reflecting an increase of 6.9%[28]. Cash Flow - The net cash flow from operating activities for the year-to-date was CNY -43,725,373.90, a decrease of 118.82% year-on-year[3]. - Cash flow from operating activities for the first three quarters of 2025 showed a net outflow of approximately ¥43.73 million, contrasting with a net inflow of ¥232.36 million in 2024[24]. - The net cash flow from operating activities for the first three quarters of 2025 was negative CNY 43,255,140.30, an improvement from negative CNY 503,618,784.01 in 2024[32]. - The net cash flow from investing activities was CNY 736,019,678.40 in 2025, up from CNY 598,213,402.69 in 2024, showing an increase of approximately 23.1%[33]. - The net cash flow from financing activities was negative at CNY -395,881,978.30, contrasting with a positive flow of CNY 278,003,477.45 in the previous year[25]. Shareholder Information - The company reported a total of 60,309 common shareholders at the end of the reporting period[9]. - The top shareholder, Shaoguan Gaoteng Enterprise Management Co., Ltd., held 16.20% of the shares, totaling 247,772,048 shares[10]. - The number of shares held by the top ten shareholders includes 247.77 million shares held by Shaoguan Gaoteng Enterprise Management Co., Ltd.[11]. Investment and Financial Expenses - The company reported interest expenses of CNY 423,646,876.19 for the current period, a decrease from CNY 460,420,091.31 in the previous year[30]. - The investment income for the first three quarters of 2025 was CNY 2,200,892,416.48, compared to CNY 1,361,867,969.86 in 2024, reflecting an increase of approximately 61.5%[30]. - The company incurred financial expenses totaling CNY 221,839,091.53, a slight decrease from CNY 234,141,088.55 in the previous year[30].

Core Viewpoint - Liaoning Chengda's stock price has shown a positive trend with a year-to-date increase of 20.72%, reflecting strong market interest and performance in the pharmaceutical and financial sectors [1][2]. Financial Performance - For the first half of 2025, Liaoning Chengda reported operating revenue of 5.348 billion yuan, a slight decrease of 0.83% year-on-year, while net profit attributable to shareholders increased by 56.18% to 718 million yuan [2]. - Cumulative cash dividends since the company's A-share listing amount to 2.11 billion yuan, with 411 million yuan distributed over the past three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders decreased by 5.14% to 66,000, while the average number of tradable shares per person increased by 5.42% to 23,173 shares [2]. - The top ten circulating shareholders include significant institutional investors, with notable increases in holdings from Southern CSI 500 ETF and Hong Kong Central Clearing Limited [3]. Stock Market Activity - On October 27, the stock price rose by 2.13% to 12.47 yuan per share, with a trading volume of 161 million yuan and a turnover rate of 0.85% [1]. - The net inflow of main funds was 7.2843 million yuan, indicating strong buying interest, particularly from large orders [1].

Core Viewpoint - Liaoning Chengda announced that the company has no overdue external guarantees [2] Group 1 - The announcement was made on the evening of October 20 [2] - The company is in a stable financial position with no overdue external guarantees [2]

证券代码：600739 证券简称：辽宁成大 公告编号：2025-076 关于为控股子公司融资提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | 保 | 被担保人名称 本次担保金额 | 10,000.00 | 辽宁成大国际贸易有限公司 万元 | | | --- | --- | --- | --- | --- | | 担 | | | | | | 对象 | 实际为其提供的担保余额（含本 次） | 58,460.50 | 万元 | | | | 是否在前期预计额度内 | 是 | □否 | □不适用：_________ | | | 本次担保是否有反担保 | 是 | 否 | □不适用：_________ | 累计担保情况 | 对外担保逾期的累计金额（万元） | 0 | | --- | --- | | 截至本公告日公司及控股子公司 | 706,600.00 | | 已批准的对外担保总额（万元） | | | 已批准的对外担保总额占公司最 | 24.12% | | 近一期经审计净资产的 ...

Core Viewpoint - Liaoning Chengda's stock price decreased by 2.06% on October 16, 2023, with a current price of 12.39 CNY per share and a total market capitalization of 18.953 billion CNY [1] Financial Performance - For the first half of 2025, Liaoning Chengda reported revenue of 5.348 billion CNY, a year-on-year decrease of 0.83%, while net profit attributable to shareholders increased by 56.18% to 718 million CNY [1] - The company has cumulatively distributed dividends of 2.11 billion CNY since its A-share listing, with 411 million CNY distributed over the past three years [2] Stock Market Activity - As of October 16, 2023, the stock experienced a net outflow of 17.3381 million CNY from main funds, with significant selling pressure observed [1] - The stock has seen a year-to-date increase of 19.94%, with a slight decline of 0.48% over the last five trading days [1] Shareholder Information - As of June 30, 2025, the number of shareholders decreased by 5.14% to 66,000, while the average number of circulating shares per person increased by 5.42% to 23,173 shares [1] - Notable institutional holdings include Southern CSI 500 ETF, which increased its holdings by 1.9215 million shares, and Hong Kong Central Clearing Limited, which increased its holdings by 1.5646 million shares [2]

Market Overview - The biopharmaceutical sector experienced a decline of 1.28% on October 13, with Baipusais leading the drop [1] - The Shanghai Composite Index closed at 3889.5, down 0.19%, while the Shenzhen Component Index closed at 13231.47, down 0.93% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Teabo Bio (688278) with a closing price of 83.89, up 2.91% [1] - ST Sihuan (000518) with a closing price of 2.42, up 2.11% [1] - Wanzhe Co. (000534) with a closing price of 15.88, up 1.99% [1] - Major decliners included: - Baipusais (301080) with a closing price of 57.65, down 6.11% [2] - Changchun High-tech (000661) with a closing price of 132.06, down 3.11% [2] - Tibet Pharmaceutical (600211) with a closing price of 47.50, down 2.84% [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 432 million yuan from institutional investors, while retail investors contributed a net inflow of 246 million yuan [2] - The capital flow for specific stocks showed: - Changchun High-tech (000661) had a net outflow of 51.35 million yuan from institutional investors [3] - Baipusais (301080) experienced a net inflow of 8.11 million yuan from institutional investors [3] - SanSheng GuoJian (688336) had a net inflow of 9.14 million yuan from institutional investors [3]

Core Viewpoint - Liaoning Chengda Co., Ltd. has successfully completed the repayment of its third short-term financing bond for the year 2024, which was issued at a total amount of 700 million RMB with a maturity of one year and an interest rate of 2.9% [1][1][1] Summary by Sections Financing Details - The company registered a short-term financing bond issuance limit of up to 2 billion RMB as approved in the 2021 annual shareholders' meeting [1] - The third short-term financing bond for 2024 was issued on September 26, 2024, amounting to 700 million RMB [1][1] - The bond had a face value price of 100 RMB per 100 RMB face value [1] Repayment Information - The third short-term financing bond matured on September 27, 2025, and the company has completed the repayment of both principal and interest [1][1][1]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：600739 证券简称：辽宁成大 公告编号：2025-075 辽宁成大股份有限公司 2025年第三次临时股东会决议公告 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 444 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 695,822,141 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 45.7081 | | 份总数的比例（%） | | (四) 表决方式是否符合《公司法》及《公司章程》的规定，股东会主持情况 等。 本次会议由董事会提议召开，由董事长徐飚先生主持，以记名投票方式表决。 (一) 股东会召开的时间：2025 年 9 月 30 日 (二) 股东会召开的地点：公司会议室 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： 会议采用现场投票和网络投票相结合的方式进行。会议的召开、表决方式符合《公 司法》及《公司章程》的规 ...

辽宁恒信律师事务所 关于辽宁成大股份有限公司2025年第三次临时股东会的 法律意见书 致：辽宁成大股份有限公司 辽宁恒信律师事务所（以下简称"本所"）接受辽宁成大股份有限公司（以 下简称"公司"）的委托，指派张贞东律师、于璇聪律师（以下简称"本所律师"） 出席公司2025年第三次临时股东会（以下简称"本次股东会"），并对本次股东 会的合法性进行见证。 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以下 简称"《股东会规则》"）等有关法律、法规和规范性文件以及《辽宁成大股份 有限公司章程》（以下简称"《公司章程》"），本所律师审查了公司提供的如 下文件： 辽宁恒信律师事务所 法律意见书 1. 公司现行的《公司章程》； 2. 公司于2025年8月29日召开的第十一届董事会第六次会议的《董事会决 议》； 3. 公司于2025年8月30日刊登于《中国证券报》《上海证券报》《证券时报》 《证券日报》与上海证券交易所网站（http://www.sse.com.cn）的《辽宁成大股 份有限公司第十一届董事会第六次会议决议公告》；公司于2 ...